CD8A and infection: Of the rituximab-treated individuals with subsequent infections (n = 15), there were no significant differences in lymphocyte counts, Ab levels, and CD4 or CD8 T cell responses after vaccination but before infection, compared with people who were not infected in the time period considered here (n = 45) (Figure 5).